Hims & Hers' stock is soaring since I rated the stock as a buy.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA23 Sept 2025, 21:14 UTC
AI-generated source summary
The video provides a fundamental analysis of HIMS stock, downgrading its rating from 'buy' to 'hold'. On August 5, 2025, HIMS was rated as a 'buy' when its stock was trading at a lower valuation. The stock is up almost 30% in the last month. HIMS experienced revenue growth, from $0.1 billion in 2020 to $2 billion in 2025. The company's operating profit margin has improved from -39% in 2021 to 6.5% in 2025. It is now trading at a forward P/E of 79.41. The analyst's intrinsic value per share is $45.81. Considering the current market price and the risk compared to the weight loss treatment, a hold rating is recommended.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.